Aardvark Therapeutics, Inc. (AARD) 8-K Current Report: February 27, 2026
Filed: February 27, 2026
Health Care
Pharmaceutical PreparationsAardvark Therapeutics, Inc. (AARD) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Aardvark Therapeutics, Inc. 8-K Feb 27, 2026 Event Analysis
Item 8.01 · Other Events
- • Voluntary pause of Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome hyperphagia — a major clinical setback
- • Trial suspension signals potential safety signal, enrollment issue, or regulatory concern; reason not disclosed in Item 8.01
- • Phase 3 halt is high-stakes: PWS is a rare disease with no approved hyperphagia treatment, making ARD-101 a key pipeline asset
- • Investors should review Exhibit 99.1 press release for root cause, timeline for resumption, and any FDA involvement
Get deeper insights on Aardvark Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.